Premium
Diet and genetic‐induced differences in the intestinal microbiome relate to cardiometabolic phenotype (637.13)
Author(s) -
O'Connor Annalouise,
Lin Fred,
Quizon Pamela,
Nestor Allison,
Albright Jody,
Bennett Brian
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.637.13
Subject(s) - microbiome , biology , trimethylamine n oxide , cholic acid , metabolic control analysis , genetics , phenotype , gut microbiome , endocrinology , insulin , medicine , gene , biochemistry , bile acid , trimethylamine
This study aimed to understand how diet and genetics influence the intestinal microbiome and cardiometabolic risk factors. To achieve this aim, inbred mouse strains varying in metabolic disease susceptibility were selected as follows: C57Bl/6J, A/J, 129S1/SvlmJ, NOD/LtJ, NZO/HilLtJ, CAST/EiJ, PWK/PhJ, WSB/EiJ. All strains were randomized to receive either an atherogenic high fat cholic acid diet or control diet for 16 weeks. Before and after this diet period, the intestinal microbiome community was assessed by 16s rRNA gene sequencing, and plasma trimethylamine‐N‐oxide (TMAO), lipids, glucose and insulin concentrations were measured. Aortic lesions were measured at the study close. Principal Coordinates Analysis highlighted by‐strain separation in microbial diversity at baseline. Between‐diet separation in community diversity was also observed. Interestingly, a strain X diet interaction was evident, with certain strains exhibiting greater separation between the atherogenic and control diets. Several differentially abundant taxa were consistently related to the cardiometabolic parameters. In conclusion, this study has identified diet and genetic‐regulated taxa related to metabolic risk factors. Future work will focus on directly investigating these taxa in order to understand mechanism of effect, and to develop targeted microbiome‐focused treatments for metabolic disease.